Ensysce Biosciences Inc Total Liabilities
Ensysce Biosciences Inc total liabilities. Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has total liabilities worth $4.07 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Ensysce Biosciences Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ensysce Biosciences Inc (2017–2025)
Total liabilities of Ensysce Biosciences Inc from 2017 to 2025. This chart illustrates how Ensysce Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Ensysce Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Ensysce Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Northann Corp.
NYSE MKT:NCL
|
USA | $11.43 Million |
|
Tantech Holdings Ltd
NASDAQ:TANH
|
USA | $13.63 Million |
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
USA | $10.72 Million |
|
Aterian Inc
NASDAQ:ATER
|
USA | $14.35 Million |
|
ECP Emerging Growth Ltd
AU:ECP
|
Australia | AU$10.43 Million |
|
Hemostemix Inc
V:HEM
|
Canada | CA$4.80 Million |
|
Shanghai Broadband Technology Co Ltd
SHG:600608
|
China | CN¥61.81 Million |
|
Warisan TC Holdings Bhd
KLSE:5016
|
Malaysia | RM661.03 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Ensysce Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ensysce Biosciences Inc total assets.
Liquidity & Leverage Metrics
Ensysce Biosciences Inc Total Liabilities Ratios Explained
Ensysce Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ensysce Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual total liabilities of Ensysce Biosciences Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.57 Million | +106.00% |
| 2024-12-31 | $2.22 Million | -34.00% |
| 2023-12-31 | $3.36 Million | -66.12% |
| 2022-12-31 | $9.91 Million | -59.66% |
| 2021-12-31 | $24.58 Million | +250.56% |
| 2020-12-31 | $7.01 Million | -32.19% |
| 2019-12-31 | $10.34 Million | +38.95% |
| 2018-12-31 | $7.44 Million | +3.96% |
| 2017-12-31 | $7.16 Million | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more